 Bruker posted better-than-expected second quarter results, as the company is seeing a broad recovery across its academic, applied, clinical, and industrial end-markets. Project Accelerate 2.0 is the next iteration of an already-successful program to refocus the companys core technologies and capabilities on growth markets in life sciences and diagnostics. 